Importantly, DHCR24 inhibition by SH42 decreases plasma FFA and CE levels, without increasing plasma total TAG and DAG levels (Fig 3), which implies that LXRα activation by desmosterol, in contrast to synthetic agonists, does not lead to hyperlipidemia. The gene discussed is NR1H3; the disease is hyperlipidemia.